Opioid/Benzodiazepine Polydrug Abuse: Aim 3
In this study, the investigators will measure affective, neurocognitive and behavioral outcomes related to chronic use of opioids and benzodiazepines (screening phase), and in response to the administration of the opioid morphine, the benzodiazepine alprazolam, morphine then alprazolam, alprazolam then morphine, morphi
| Condition(s) | Opioid Abuse, Benzodiazepine Abuse, Polysubstance Abuse |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | In this study, the investigators will measure affective, neurocognitive and behavioral outcomes related to chronic use of opioids and benzodiazepines (screening phase), and in response to the administration of the opioid morphine, the benzodiazepine alprazolam, morphine then alprazolam, alprazolam then morphine, morphine+alprazolam simultaneously, and placebo (laboratory pharmacology experiment). The latter will enable the investigators to assess the effects of an opioid alone, benzodiazepine alone, concurrent and simultaneous administration of opioid+benzodiazepine, relative to a placebo control. |
| Who can participate | Inclusion Criteria: * must self-report past 10-year experience taking opioid and sedative drugs (for therapeutic or non-therapeutic reasons), but not necessarily at the same time. As an alternative to the sedative drug exposure requirement, participants must have used alcohol on at least 3 separate days during the past month. Participants may have current mild- or moderate-severity Opioid Use Disorder or current mild- or moderate-severity Sedative Use Disorder; * must not be seeking treatment for their substance use problems; * must be in current good overall health Exclusion Criteria: * meet DSM-5 criteria for current psychosis, bipolar disorder, or severe depression (i.e. severe psychiatric disorder); * meet DSM-5 criteria for severe substance use disorder for any substance (e.g. Sedativ |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Lead sponsor | Wayne State University |
| Locations | Detroit, Michigan, United States |
| Start date | 2024-03-13 |
| NCT ID | NCT05006079 |
| Official listing | https://clinicaltrials.gov/study/NCT05006079 |